Stereotaxis Reports 2020 Third Quarter Financial Results

Saint Louis, Missouri, UNITED STATES

ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020.

“Stereotaxis is pleased to report revenue growth with the successful installation of the first Genesis RMN® and Model S Imaging Systems in both the United States and Europe. Our newest robotic technology has performed to the high expectations demanded by premier medical institutions, been used successfully in over ninety procedures, and proven reliable and robust with uninterrupted up-time,” said David Fischel, Chairman and CEO.

“While hospitals remain negatively impacted by COVID-19, we have experienced a gradual return towards more normal capital planning. We received an additional order for a Genesis system from a US hospital that is establishing a new robotic electrophysiology program. Given the advanced status of multiple additional discussions, we are comfortable providing preliminary guidance for $10-20 million in Genesis system revenue in 2021.”

“Stereotaxis’ advanced robotically-navigated magnetic ablation catheter is advancing on schedule with initial commercialization and initiation of a pivotal US trial expected in 2021. Meaningful progress continues on an additional wave of innovations within electrophysiology and beyond that are expected to drive transformational revenue growth. We expect to share details on this next wave of innovation towards the end of next year.”

Third Quarter 2020 Financial Results
Revenue for the third quarter of 2020 totaled $8.7 million, up 6% from $8.2 million in the prior year third quarter. System revenue was $3.0 million reflecting initial revenue recognition on the first Genesis RMN® Systems. Recurring revenue was $5.5 million in the quarter, compared to $6.3 million in the prior year third quarter. The decline was primarily caused by a 10% reduction in procedure volumes due to COVID-19.

Gross margin in the quarter was $4.7 million, or 54% of revenue. Gross margin on recurring revenue was consistent with prior quarters. Gross margin on system revenue reflected the allocation of overhead expenses and initial installation costs, and was not reflective of cash margins generated from the system sales or expected future GAAP margins. Operating expenses in the third quarter of $6.2 million decreased from $6.4 million in the prior year quarter with increased investment in R&D offset by reduced travel and marketing expenses. Operating loss and net loss in the quarter were ($1.6) million. Adjusted negative free cash flow for the quarter was ($0.2) million.

Cash Balance and Liquidity
At September 30, 2020, Stereotaxis had cash and cash equivalents of $43.8 million.

Forward Looking Expectations
Stereotaxis continues to experience significant interest in the Genesis system and anticipates robust double-digit revenue growth in 2021, with Genesis RMN System revenue of $10-20 million. Stereotaxis is increasing its previously provided guidance for year-end cash balance and now anticipates ending 2020 with greater than $43 million cash and cash equivalents. Stereotaxis’ balance sheet allows it to reach profitability without the need for additional financings.

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, November 9, 2020, at 10:00 a.m. Eastern Time. To access the conference call, dial 1-800-437-2398 (US and Canada) or 1-856-344-9206 (International) and give the participant pass code 9232669. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery
Chief Financial Officer


 Three Months Ended September 30, Nine Months Ended September 30,
 2020 2019 2020 2019
Systems$2,953,005  $1,696,964  $2,965,774  $1,755,015 
Disposables, service and accessories 5,504,048   6,258,252   16,099,915   19,515,125 
Sublease 246,530   246,532   739,590   739,593 
Total revenue 8,703,583   8,201,748   19,805,279   22,009,733 
Cost of revenue:       
Systems 3,031,440   665,463   3,253,976   722,828 
Disposables, service and accessories 747,285   919,599   2,068,085   2,928,718 
Sublease 246,530   246,531   739,590   739,592 
Total cost of revenue 4,025,255   1,831,593   6,061,651   4,391,138 
Gross margin 4,678,328   6,370,155   13,743,628   17,618,595 
Operating expenses:       
Research and development 1,952,641   1,751,081   6,038,753   7,405,462 
Sales and marketing 2,822,680   3,120,632   8,279,853   9,666,975 
General and administrative 1,466,046   1,539,648   4,962,227   4,186,277 
Total operating expenses 6,241,367   6,411,361   19,280,833   21,258,714 
Operating loss (1,563,039)  (41,206)  (5,537,205)  (3,640,119)
Interest income (expense) (9,933)  84,954   71,596   133,329 
Net income (loss)$(1,572,972) $43,748  $(5,465,609) $(3,506,790)
Cumulative dividend on convertible preferred stock (343,101)  (360,647)  (1,028,950)  (1,071,351)
Net loss attributable to common stockholders$(1,916,073) $(316,899) $(6,494,559) $(4,578,141)
Net loss per share attributed to common stockholder:       
Basic$(0.03) $(0.00) $(0.09) $(0.07)
Diluted$(0.03) $(0.00) $(0.09) $(0.07)
Weighted average number of common shares and equivalents:       
Basic 74,488,771   64,294,153   72,004,956   61,405,083 
Diluted 74,488,771   64,294,153   72,004,956   61,405,083 

 September 30, 2020 December 31, 2019
Current assets:   
Cash and cash equivalents$43,595,829  $30,182,115 
Compensating cash arrangement 250,295   - 
Accounts receivable, net of allowance of $265,233 and $380,212 at 2020 and 2019, respectively 5,409,722   5,329,577 
Inventories, net 2,846,051   1,847,530 
Prepaid expenses and other current assets 1,774,792   1,470,922 
Total current assets 53,876,689   38,830,144 
Property and equipment, net 234,858   250,443 
Operating lease right-of-use assets 2,764,022   4,286,064 
Other assets 256,669   218,103 
Total assets$57,132,238  $43,584,754 
Liabilities and stockholders' equity   
Current liabilities:   
Short-term debt$457,244  $- 
Accounts payable 1,568,581   2,099,097 
Accrued liabilities 2,956,130   2,721,104 
Deferred revenue 6,189,796   5,092,455 
Current portion of operating lease liabilities 2,275,436   2,248,189 
Total current liabilities 13,447,187   12,160,845 
Long-term debt 1,701,066   - 
Long-term deferred revenue 569,475   554,258 
Operating lease liabilities 540,536   2,089,537 
Other liabilities 255,517   255,517 
Total liabilities 16,513,781   15,060,157 
Series A - Convertible preferred stock:   
Convertible preferred stock, Series A, par value $0.001; 22,513 and 23,110 shares outstanding at 2020 and 2019, respectively 5,605,323   5,758,190 
Stockholders' equity:   
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 at 2020 and 2019 5,610   5,610 
Common stock, par value $0.001; 300,000,000 shares authorized, 73,678,206 and 68,529,623 shares issued at 2020 and 2019, respectively 73,678   68,530 
Additional paid-in capital 521,918,228   504,211,040 
Treasury stock, 4,015 shares at 2020 and 2019 (205,999)  (205,999)
Accumulated deficit (486,778,383)  (481,312,774)
Total stockholders' equity 35,013,134   22,766,407 
Total liabilities and stockholders' equity$57,132,238  $43,584,754